Anti-MMP13 antibody [M33] (ab1010)


  • Product nameAnti-MMP13 antibody [M33]
    See all MMP13 primary antibodies
  • Description
    Mouse monoclonal [M33] to MMP13
  • SpecificityBased on Western blotting, the antibody reacts with human procollagenase-3. The antibody does not cross react with MT1-MMP latent form (MMP-14), MT2-MMP catalytic domain (MMP-15), MT3-MMP catalytic domain (MMP-16), MT4-MMP catalytic domain (MMP-17), MT5-MMP catalytic domain (MMP-18), Gelatinase A (MMP-2) latent form, Gelatinase B (MMP-9) latent form or Collagenase 2 (MMP-8) latent form.
  • Tested applicationsSuitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant human procollagenase-3 expressed in insect cells

  • General notesMMP is Matrix Metalloproteinase.



Our Abpromise guarantee covers the use of ab1010 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000. Detects a band of approximately 50 kDa (predicted molecular weight: 53 kDa).
ELISA 1/2000.


  • FunctionDegrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process.
  • Tissue specificitySeems to be specific to breast carcinomas.
  • Involvement in diseaseDefects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.
    Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
  • Sequence similaritiesBelongs to the peptidase M10A family.
    Contains 4 hemopexin-like domains.
  • DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
  • Cellular localizationSecreted > extracellular space > extracellular matrix.
  • Information by UniProt
  • Database links
  • Alternative names
    • CLG 3 antibody
    • CLG3 antibody
    • Collagenase 3 antibody
    • Collagenase3 antibody
    • MANDP1 antibody
    • Matrix metallopeptidase 13 (collagenase 3) antibody
    • Matrix Metalloproteinase 13 antibody
    • Matrix metalloproteinase-13 antibody
    • MMP 13 antibody
    • MMP-13 antibody
    • Mmp13 antibody
    • MMP13_HUMAN antibody
    see all

References for Anti-MMP13 antibody [M33] (ab1010)

ab1010 has not yet been referenced specifically in any publications.

Product Wall

My sincere apologies for the delay in replying to you, we have tried to find out if the epitope has been mapped but I can confirm that it has not been mapped and therefore we do not know which portion of MMP13 is recognized by the antibody. Sorry I...

Read More